Cytosorbents EBITDA 2010-2024 | CTSO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cytosorbents ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cytosorbents ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$199.9B
Stryker (SYK)	$137.7B
Boston Scientific (BSX)	$121.6B
Medtronic (MDT)	$113B
EssilorLuxottica (ESLOY)	$104.4B
Haleon (HLN)	$48.1B
Lonza Group Ag (LZAGY)	$45.4B
ResMed (RMD)	$35B
Koninklijke Philips (PHG)	$29B
Terumo (TRUMY)	$27.9B
Zimmer Biomet Holdings (ZBH)	$21.6B
Baxter (BAX)	$20.1B
Insulet (PODD)	$16.6B
Smith & Nephew SNATS (SNN)	$13.4B
Bio-Rad Laboratories (BIO)	$9.5B
Demant (WILYY)	$9.2B
BellRing Brands (BRBR)	$7.7B
Lantheus Holdings (LNTH)	$7.5B
ICU Medical (ICUI)	$4.3B
TG Therapeutics (TGTX)	$3.9B
Haemonetics (HAE)	$3.9B
Perrigo (PRGO)	$3.8B
GN Store Nord (GNNDY)	$3.8B
Neogen (NEOG)	$3.7B
Prestige Consumer Healthcare (PBH)	$3.6B
Envista Holdings (NVST)	$3.3B
QuidelOrtho (QDEL)	$3.1B
Agios Pharmaceuticals (AGIO)	$2.6B
Maravai LifeSciences Holdings (MRVI)	$2.3B
Green Thumb Industries (GTBIF)	$2.2B